The state of Texas currently has 27 active clinical trials seeking participants for Migraine research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Recruiting
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
03/25/2024
Locations: Dell Children's Medical Center, Austin, Texas +14 locations
Conditions: Pediatric Migraine
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
Recruiting
The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: FutureSearch Trials of Neurology, Austin, Texas +3 locations
Conditions: Migraine
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
Recruiting
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine. The study hypothesis is that in pediatric participants with chronic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
03/20/2024
Locations: Helios Clinical Research Inc, Burleson, Texas +1 locations
Conditions: Migraine
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
Recruiting
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
03/20/2024
Locations: Helios Clinical Research Inc, Burleson, Texas +1 locations
Conditions: Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Recruiting
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolescents (≥ 6 to < 18 years of age).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
03/19/2024
Locations: Dell Children's Medical Center, Austin, Texas +12 locations
Conditions: Acute Treatment of Migraine
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Recruiting
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and adolescents (a... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
03/18/2024
Locations: UT Health Austin at Dell Children's Neurology Clinic /ID# 244266, Austin, Texas +16 locations
Conditions: Migraine
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
Recruiting
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Red Star Research, LLC, Lake Jackson, Texas +1 locations
Conditions: Migraine
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Recruiting
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for pediatric participants. The main goal of the study is to evaluate the safety and efficacy (how well treatment works) of a low-dose and high-dose of atogepant in pediatric par... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
03/18/2024
Locations: FutureSearch Trials of Neurology /ID# 247470, Austin, Texas +4 locations
Conditions: Episodic Migraine
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
Recruiting
Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins). Treatment of MOH usually involves reducing the dose of or discontinuing acute medications. Eptinezumab is a medication used for the preventive treatment of migraine in adults. The main goals of this trial are to learn whether eptinezumab helps reduce the number of days with migraine, the number of days with h... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/12/2024
Locations: Texas Center for Drug Development, Inc, Houston, Texas
Conditions: Migraine, Medication Overuse Headache
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
Recruiting
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Chronic migraine is defined as having at least 15 days of headache a month with at least 8 of those days being migraine headache day... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: North Texas Institute of Neurology & Headache, Frisco, Texas +2 locations
Conditions: Chronic Migraine
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
Recruiting
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Episodic Migraine is defined as having less than 15 days of headache a month with at least 6 days with migraine headaches. Migrain... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: North Texas Institute of Neurology & Headache, Frisco, Texas +2 locations
Conditions: Episodic Migraine
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Recruiting
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to <18 years with episodic migraine.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
03/11/2024
Locations: DCT-Baxter Research, LLC dba Discovery Clinical Trials, Dallas, Texas +9 locations
Conditions: Migraine